The molecular pathology of cognitive decline: Focus on metals

In the past two decades there have been significant advances made in understanding the cellular and molecular alterations that occur with brain ageing, as well as with our understanding of age-related brain diseases. Ageing is associated with a mid-life decline in many cognitive domains (eg. Attenti...

Full description

Bibliographic Details
Format: eBook
Language:English
Published: Frontiers Media SA 2016
Series:Frontiers Research Topics
Subjects:
TBI
Online Access:Open Access: DOAB, download the publication
Open Access: DOAB: description of the publication
LEADER 03400namaa2200505uu 4500
001 doab53855
003 oapen
005 20210211
006 m o d
007 cr|mn|---annan
008 210211s2016 xx |||||o ||| 0|eng d
020 |a 978-2-88919-720-0 
020 |a 9782889197200 
024 7 |a 10.3389/978-2-88919-720-0  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a PSAN  |2 bicssc 
720 1 |a Roger Chung  |4 aut 
720 1 |a Paul A. Adlard  |4 aut 
245 0 0 |a The molecular pathology of cognitive decline: Focus on metals 
260 |b Frontiers Media SA  |c 2016 
300 |a 1 online resource (175 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers Research Topics 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a In the past two decades there have been significant advances made in understanding the cellular and molecular alterations that occur with brain ageing, as well as with our understanding of age-related brain diseases. Ageing is associated with a mid-life decline in many cognitive domains (eg. Attention, working memory, episodic memory) that progresses with advancing age and which may be potentiated by a variety of diseases. However, despite the breadth of attempts to explain it, the underlying basis for age-related memory impairment remains poorly understood. Both normal and "pathological" ageing (as in age-related neurodegenerative disorders such as Alzheimer's disease) may be associated with overlapping and increased levels of "abnormal" pathology, and this may be a potential mediator of cognitive decline in both populations. An emerging hypothesis in this field is that metal ion dys/homeostasis may represent a primary unifying mechanism to explain age- and disease-associated memory impairment - either indirectly via an effect on disease pathogenesis, or by a direct effect on signaling pathways relevant to learning and memory. There remains a concerted worldwide effort to deliver an effective therapeutic treatment for cognitive decline associated with ageing and/or disease, which is currently an unmet need. There have been numerous clinical trials conducted specifically testing drugs to prevent cognitive decline and progression to dementia, but to date the results have been less than impressive, highlighting the urgent need for a greater understanding of the neurobiological basis of memory impairment in ageing and disease which can then drive the search for effective therapeutics. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Neurosciences  |2 bicssc 
653 |a aluminium 
653 |a Alzheimer's disease 
653 |a Amyotrophic Lateral Sclerosis 
653 |a Cognition 
653 |a Copper 
653 |a Down Syndrome 
653 |a Iron 
653 |a Parkinson's disease 
653 |a TBI 
653 |a Zinc 
793 0 |a DOAB Library. 
856 4 0 |u http://journal.frontiersin.org/researchtopic/1341/the-molecular-pathology-of-cognitive-decline-focus-on-metals  |7 0  |z Open Access: DOAB, download the publication 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/53855  |7 0  |z Open Access: DOAB: description of the publication